Product Description
iPSC Gamma-Delta T Cells. Our DeltEx platform has expanded its capabilities to include iPSC derived gamma-delta T cells. We were the first company to demonstrate the ability to generate both iPSC derived Vd1+ and Vd2+ gamma-delta T cell subtypes using cell-type specific differentiation processes. iPSC-derived gamma-delta cells could address existing challenges, including of donor sourcing and limitations of cell expansion in manufacturing. iPSCs, with their nearly unlimited self-renewal capacity and multi-lineage differentiation potential, offer the ability to to generate potentially ‘off-the-shelf’ therapeutic products for patients across a wide range of cancers. (Sourced from: https://in8bio.com/pipeline/)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: IN8bio
Company Location: NEW YORK NY 10016
Company CEO: William Ho
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for INB-500](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Hematological Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|